<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>TogoPeptide Research Library</title>
    <link>https://togopeptide.com/blog/</link>
    <description>Long-form research articles on peptide pharmacology, comparison studies, and laboratory methodology. Research-frame language with peer-reviewed citations.</description>
    <language>en</language>
    <copyright>© 2026 TogoPeptide / TNF Business</copyright>
    <managingEditor>info@togopeptide.com (TogoPeptide Research Editorial)</managingEditor>
    <webMaster>info@togopeptide.com (TogoPeptide)</webMaster>
    <pubDate>Sat, 03 May 2026 13:00:00 +0200</pubDate>
    <lastBuildDate>Sat, 03 May 2026 13:00:00 +0200</lastBuildDate>
    <category>Peptide research</category>
    <generator>TogoPeptide v2</generator>
    <docs>https://www.rssboard.org/rss-specification</docs>
    <ttl>1440</ttl>
    <image>
      <url>https://togopeptide.com/assets/img/og-image.jpg</url>
      <title>TogoPeptide Research Library</title>
      <link>https://togopeptide.com/blog/</link>
    </image>
    <atom:link href="https://togopeptide.com/blog/feed.xml" rel="self" type="application/rss+xml" />

    <item>
      <title>Tesamorelin complete research guide: GHRH analog</title>
      <link>https://togopeptide.com/blog/tesamorelin-complete-guide.html</link>
      <description>Modified GHRH analog deep-dive — upstream pituitary mechanism (GHRH-receptor agonism), visceral adipose tissue research corpus, IGF-1 axis modulation, NAFLD trial outcomes. Distinct research category from GLP-1-class metabolic peptides.</description>
      <pubDate>Sat, 03 May 2026 13:30:00 +0200</pubDate>
      <guid isPermaLink="true">https://togopeptide.com/blog/tesamorelin-complete-guide.html</guid>
      <category>Pillar guide</category>
      <category>Growth-hormone axis research</category>
      <dc:creator>TogoPeptide Research Editorial</dc:creator>
    </item>

    <item>
      <title>BPC-157 mechanism deep-dive: gastric pentadecapeptide research</title>
      <link>https://togopeptide.com/blog/bpc-157-mechanism-deep-dive.html</link>
      <description>Multi-pathway mechanism of the gastric pentadecapeptide — NO-synthase, VEGF angiogenesis, growth-hormone receptor expression, dopaminergic effects. Tendon, mucosa and vascular research models.</description>
      <pubDate>Sat, 03 May 2026 13:00:00 +0200</pubDate>
      <guid isPermaLink="true">https://togopeptide.com/blog/bpc-157-mechanism-deep-dive.html</guid>
      <category>Mechanism deep-dive</category>
      <category>Recovery research</category>
      <dc:creator>TogoPeptide Research Editorial</dc:creator>
    </item>

    <item>
      <title>Semaglutide complete research guide: foundational GLP-1 agonist</title>
      <link>https://togopeptide.com/blog/semaglutide-complete-guide.html</link>
      <description>Foundational long-acting GLP-1 receptor agonist research compound. STEP, SUSTAIN, PIONEER, SELECT trial corpus. Structure modifications, mechanism, half-life, handling.</description>
      <pubDate>Sat, 03 May 2026 12:30:00 +0200</pubDate>
      <guid isPermaLink="true">https://togopeptide.com/blog/semaglutide-complete-guide.html</guid>
      <category>Pillar guide</category>
      <category>Fat loss research</category>
      <dc:creator>TogoPeptide Research Editorial</dc:creator>
    </item>

    <item>
      <title>Retatrutide complete research guide: triple GIP/GLP-1/glucagon agonist</title>
      <link>https://togopeptide.com/blog/retatrutide-complete-guide.html</link>
      <description>Triple receptor agonist deep-dive — phase-2 trial literature, hepatic energy expenditure mechanism, body-composition outcomes. The largest published body-weight changes in this peptide class.</description>
      <pubDate>Sat, 03 May 2026 12:00:00 +0200</pubDate>
      <guid isPermaLink="true">https://togopeptide.com/blog/retatrutide-complete-guide.html</guid>
      <category>Pillar guide</category>
      <category>Fat loss research</category>
      <dc:creator>TogoPeptide Research Editorial</dc:creator>
    </item>

    <item>
      <title>Tirzepatide complete research guide: dual GIP/GLP-1 agonist</title>
      <link>https://togopeptide.com/blog/tirzepatide-complete-guide.html</link>
      <description>Dual receptor agonist deep-dive — structure (39 aa, Aib substitutions, C20 fatty-acid albumin binding), mechanism, SURPASS / SURMOUNT trial corpus, half-life, handling.</description>
      <pubDate>Sat, 03 May 2026 11:30:00 +0200</pubDate>
      <guid isPermaLink="true">https://togopeptide.com/blog/tirzepatide-complete-guide.html</guid>
      <category>Pillar guide</category>
      <category>Fat loss research</category>
      <dc:creator>TogoPeptide Research Editorial</dc:creator>
    </item>

    <item>
      <title>Reconstitution methodology for lyophilized research peptides</title>
      <link>https://togopeptide.com/blog/reconstitution-methodology.html</link>
      <description>Bacteriostatic water vs acetic acid water, dilution math, multi-puncture handling, storage windows. Documented research-handling literature for lyophilized peptide reconstitution.</description>
      <pubDate>Sat, 03 May 2026 11:00:00 +0200</pubDate>
      <guid isPermaLink="true">https://togopeptide.com/blog/reconstitution-methodology.html</guid>
      <category>Methodology</category>
      <category>Research handling</category>
      <dc:creator>TogoPeptide Research Editorial</dc:creator>
    </item>

    <item>
      <title>How to read a Certificate of Analysis (COA) for research peptides</title>
      <link>https://togopeptide.com/blog/how-to-read-coa.html</link>
      <description>Methodology guide on reading research-peptide COAs: HPLC chromatograms, mass-spectrometry identity confirmation, water content, endotoxin levels, lot traceability — what every line means.</description>
      <pubDate>Sat, 03 May 2026 10:30:00 +0200</pubDate>
      <guid isPermaLink="true">https://togopeptide.com/blog/how-to-read-coa.html</guid>
      <category>Methodology</category>
      <category>Quality control</category>
      <dc:creator>TogoPeptide Research Editorial</dc:creator>
    </item>

    <item>
      <title>GLP-1 agonists compared: Semaglutide, Tirzepatide, Retatrutide</title>
      <link>https://togopeptide.com/blog/glp-1-agonists-comparison.html</link>
      <description>Research-progression overview through the published literature — single-agonist (Semaglutide), dual GIP/GLP-1 (Tirzepatide), triple GIP/GLP-1/glucagon (Retatrutide). Side-by-side identifiers, mechanisms, half-lives.</description>
      <pubDate>Sat, 03 May 2026 10:00:00 +0200</pubDate>
      <guid isPermaLink="true">https://togopeptide.com/blog/glp-1-agonists-comparison.html</guid>
      <category>Pillar guide</category>
      <category>Comparison study</category>
      <dc:creator>TogoPeptide Research Editorial</dc:creator>
    </item>

    <item>
      <title>BPC-157 vs TB-500: a research-frame comparison</title>
      <link>https://togopeptide.com/blog/bpc-157-vs-tb-500.html</link>
      <description>Two pentadecapeptides studied in tissue-repair literature, often co-investigated. Side-by-side comparison: structure, mechanism class, half-life characteristics, peer-reviewed citations.</description>
      <pubDate>Fri, 01 May 2026 10:00:00 +0200</pubDate>
      <guid isPermaLink="true">https://togopeptide.com/blog/bpc-157-vs-tb-500.html</guid>
      <category>Comparison study</category>
      <category>Recovery research</category>
      <dc:creator>TogoPeptide Research Editorial</dc:creator>
    </item>

  </channel>
</rss>
